Neuroendocrine Clinical Trials

Protocol No.PITitle
OSU-9812Albert de la ChapelleA Strategy to Search for Genes Predisposing to Papillary Carcinoma of the Thyroid When Mutated
OSU-06032Richard KloosThe Endocrine Neoplasia Repository (ENR).
OSU-07080Manisha ShahA Banking Facility for Biological Samples and Clinical Data to Study Neuroendocrine Tumors
RTOG-0912Manisha ShahA Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (Imrt), Paclitaxel and Pazopanib (Nsc 737754)/Placebo,for the Treatment of Anaplastic Thyroid Cancer
OSU-12064Manisha ShahA Randomized Phase 2 Study of single agent Dabrafenib (BRAFi) vs. combination regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in patients with BRAF mutation or BRAF gene fusion defect in thyroid carcinoma
OSU-12066Manisha ShahA Phase I Trial of GSK2118436 (BRAFi) and Pazopanib in Patients with BRAF-Mutated Advanced Malignant Tumors
OSU-12154Manisha ShahPhase II Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on First-Line VEGFR-Targeted Therapy
OSU-13070Manisha ShahPhase 2 Study of Pioglitazone in follicular-patterned thyroid cancers that contain the PAX8-PPARgamma fusion gene
ALLIANCE-A021202Manisha ShahProspective Randomized Phase II Trial of Pazopanib(NSC #737754, IND #75648) versus Placebo in Patients with Progressive Carcinoid Tumors
ECOG-E2211Manisha ShahA Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: